NASDAQ · AVR
Healthcare · Medical - Devices
$5.78
Up+$0.22 (+3.81%)
Updated Oct 28, 2026, 1:22 AM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · AVR
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
AVR closed at $5.78 after 20 trading sessions, down 23.85% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $5.85 | $5.92 | $5.74 | $5.78 | 739.31K |
| Oct 23, 2026 | $6.00 | $6.08 | $5.85 | $5.87 | 901.79K |
| Oct 22, 2026 | $5.92 | $6.17 | $5.825 | $6.00 | 2.1M |
| Oct 21, 2026 | $6.29 | $6.47 | $5.99 | $6.01 | 1.39M |
| Oct 20, 2026 | $6.20 | $6.525 | $6.175 | $6.29 | 2.83M |
| Oct 19, 2026 | $6.09 | $6.25 | $6.06 | $6.18 | 1.36M |
| Oct 16, 2026 | $6.34 | $6.34 | $6.04 | $6.05 | 1.03M |
| Oct 15, 2026 | $6.23 | $6.38 | $6.115 | $6.36 | 825.66K |
| Oct 14, 2026 | $6.33 | $6.468 | $6.095 | $6.26 | 1.74M |
| Oct 13, 2026 | $6.61 | $6.635 | $6.41 | $6.45 | 764.3K |
| Oct 12, 2026 | $6.72 | $6.7625 | $6.525 | $6.65 | 972.55K |
| Oct 9, 2026 | $6.73 | $6.90 | $6.64 | $6.77 | 1.34M |
| Oct 8, 2026 | $6.75 | $6.78 | $6.565 | $6.63 | 2.47M |
| Oct 7, 2026 | $6.83 | $7.08 | $6.76 | $6.82 | 2.45M |
| Oct 6, 2026 | $7.57 | $7.655 | $7.02 | $7.05 | 2.64M |
| Oct 5, 2026 | $7.66 | $7.745 | $7.365 | $7.55 | 1.89M |
| Oct 2, 2026 | $7.97 | $8.00 | $7.655 | $7.71 | 1.5M |
| Oct 1, 2026 | $7.74 | $7.86 | $7.52 | $7.61 | 1.17M |
| Sep 30, 2026 | $7.66 | $7.955 | $7.54 | $7.77 | 976.39K |
| Sep 29, 2026 | $7.80 | $7.84 | $7.525 | $7.59 | 782.37K |
The latest Smart Investors Daily articles mentioning AVR.
Company
Market Activity
Research & News
AVR research
Company profile and research snapshot.
Anteris Technologies Global Corp is a structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Its product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with the world's interventional cardiologists and cardiac surgeons to treat aortic stenosis a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. Company operates in USA, Germany, Australia, Switzerland, and Sweden. Majority of revenue is from USA.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 14, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 7, 2026 | Barclays | Equal-Weight | — |
| Aug 14, 2026 | Cantor Fitzgerald | Overweight | — |
| May 15, 2026 | Barclays | Overweight | — |
| Mar 27, 2026 | Cantor Fitzgerald | Overweight | — |
No generated briefing is available yet.
Yahoo · Oct 20, 2026
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has secured full German regulatory clearance for its pivotal PARADIGM trial, allowing the company to begin recruiting patients in Europe’s largest transcatheter aortic valve replacement market. Germany’s Federal Institute for Drugs and...
Yahoo · Oct 20, 2026
MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the German Federal Institute for Drugs and Medical Devices (BfArM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This clearance enables Anteris to initiate patient recruitment a
Benzinga · Oct 14, 2026
Cantor Fitzgerald analyst Gabie Ingoglia reiterates Anteris Technologies Glb (NASDAQ:AVR) with a Overweight and maintains $15 price target.
Benzinga · Oct 7, 2026
Barclays analyst Matt Miksic initiates coverage on Anteris Technologies Glb (NASDAQ:AVR) with a Equal-Weight rating and announces Price Target of $10.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning AVR.
